3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
22
Venous Thromboembolism
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
HR+HER2- Advanced Breast Cancer
1
Glioblastoma
1
Endometrial Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Cystadenocarcinoma, Serous
1
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Cisplatin
6
Bortezomib
6
Gemcitabine
5
venetoclax
4
elotuzumab
4
isatuximab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Letrozole
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
palbociclib
2
ixazomib
2
dexamethasone 21-phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
ribociclib
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled